Shopping Cart

Your shopping cart is currently empty

DCZ0415

Name: DCZ0415
Brand: TargetMol
SKU: T10981
Price: 48 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Synonyms:

Catalog No. T10981 Copy Product Info

Purity: 99.95%

😃Good

DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.

Cas No. 2242470-43-3

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$48	In Stock	In Stock
5 mg	$118	In Stock	In Stock
10 mg	$198	In Stock	In Stock
25 mg	$372	In Stock	In Stock
50 mg	$562	In Stock	In Stock
100 mg	$786	In Stock	In Stock
200 mg	$1,080	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$128	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.95%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.
In vitro	DCZ0415 demonstrated significant anti-proliferative effects: it reduced colony formation at 10-20 μM (72 hours), decreased MM cell viability in a dose-dependent manner at 1.25-40 μM (72 hours), increased apoptotic cell death at 10-20 μM (24-72 hours), induced G0/G1 cell cycle arrest at 10-20 μM (24 hours), and reduced protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB at 10 μM (48 hours). The IC50 in MM cell lines was 1.0–10 μM, and DCZ0415 exerted cytotoxicity by inhibiting DNA synthesis in MM cells.
In vivo	DCZ0415, was confirmed to bind TRIP13 using pull-down, nuclear magnetic resonance spectroscopy, and surface plasmon resonance-binding assays.?DCZ0415 induced antimyeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant patients with myeloma.?The inhibitor impaired nonhomologous end joining repair and inhibited NF-κB activity.?Moreover, combining DCZ0415 with the multiple myeloma chemotherapeutic melphalan or the HDAC inhibitor panobinostat induced synergistic antimyeloma activity.?Therefore, targeting TRIP13 may be an effective therapeutic strategy for multiple myeloma, particularly refractory or relapsed multiple myeloma.

Chemical Properties

Molecular Weight	356.42
Formula	C₂₃H₂₀N₂O₂
Cas No.	2242470-43-3
Smiles	O=C1C2C(C3C=CC2C2CC32)C(=O)N1c1ccc(Cc2ccncc2)cc1
Relative Density.	1.319 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 77 mg/mL (216.04 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Saline: < 7.69 mg/mL (21.58 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.69 mg/mL (21.58 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.8057 mL	14.0284 mL	28.0568 mL	140.2839 mL
5 mM	0.5611 mL	2.8057 mL	5.6114 mL	28.0568 mL
10 mM	0.2806 mL	1.4028 mL	2.8057 mL	14.0284 mL
20 mM	0.1403 mL	0.7014 mL	1.4028 mL	7.0142 mL
50 mM	0.0561 mL	0.2806 mL	0.5611 mL	2.8057 mL
100 mM	0.0281 mL	0.1403 mL	0.2806 mL	1.4028 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc